CTC
MRNA icon

Central Trust Company’s Moderna MRNA Stock Holding History

Central Trust Company’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.82K Buy
126
+8
+7% +$414 ﹤0.01% 1239
2026
Q1 		$6K Sell
118
-500
-81% -$23.3K ﹤0.01% 1237
2025
Q4 		$18.2K Sell
618
-92
-13% -$2.5K ﹤0.01% 1013
2025
Q3 		$18.3K Sell
710
-50
-7% -$1.4K ﹤0.01% 1006
2025
Q2 		$21K Sell
760
-1,271
-63% -$33.5K ﹤0.01% 969
2025
Q1 		$57.6K Hold
2,031
– – ﹤0.01% 759
2024
Q4 		$84.4K Sell
2,031
-6,245
-75% -$298K ﹤0.01% 692
2024
Q3 		$553K Sell
8,276
-159
-2% -$14.6K 0.01% 397
2024
Q2 		$1M Sell
8,435
-452
-5% -$57.2K 0.02% 315
2024
Q1 		$947K Sell
8,887
-1,516
-15% -$153K 0.02% 323
2023
Q4 		$1.03M Sell
10,403
-2,492
-19% -$210K 0.03% 311
2023
Q3 		$1.33M Sell
12,895
-617
-5% -$68.8K 0.04% 267
2023
Q2 		$1.64M Sell
13,512
-1,789
-12% -$239K 0.05% 238
2023
Q1 		$2.35M Sell
15,301
-1,213
-7% -$200K 0.07% 204
2022
Q4 		$2.97M Sell
16,514
-4,807
-23% -$786K 0.09% 179
2022
Q3 		$2.52M Sell
21,321
-2,359
-10% -$358K 0.09% 177
2022
Q2 		$3.38M Sell
23,680
-7,395
-24% -$1.06M 0.11% 152
2022
Q1 		$5.35M Sell
31,075
-9,165
-23% -$1.54M 0.15% 119
2021
Q4 		$10.2M Sell
40,240
-536
-1% -$157K 0.29% 72
2021
Q3 		$15.7M Sell
40,776
-5,171
-11% -$1.91M 0.56% 44
2021
Q2 		$10.8M Sell
45,947
-1,200
-3% -$214K 0.39% 57
2021
Q1 		$6.17M Buy
47,147
+1,265
+3% +$183K 0.24% 92
2020
Q4 		$4.79M Sell
45,882
-6,654
-13% -$673K 0.2% 103
2020
Q3 		$3.72M Buy
52,536
+52,457
+66,401% +$3.66M 0.17% 113
2020
Q2 		$5K Hold
79
– – ﹤0.01% 929
2020
Q1 		$2K Buy
+79
New +$1.82K ﹤0.01% 1074

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Central Trust Company's MRNA Position: Q2 2026 in Review

Central Trust Company increased its Moderna (MRNA) stake by 6.8% in Q2 2026, buying an estimated $414 and bringing the position to 126 shares worth $8.82K. The position accounts for ﹤0.01% of the portfolio, ranked #1239.

Central Trust Company first reported a position in MRNA in Q1 2020 and has held it in 26 quarters since. The position peaked at $15.7M in Q3 2021. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Central Trust Company held 126 shares of Moderna worth $8.82K as of Q2 2026.
  • Central Trust Company bought 8 Moderna shares in Q2 2026, an estimated $414.
  • Moderna made up ﹤0.01% of Central Trust Company's portfolio in Q2 2026, its #1239 holding.
  • Central Trust Company first reported a position in Moderna in Q1 2020 and has held it in 26 quarters since.
  • Central Trust Company's Moderna position peaked at $15.7M in Q3 2021.
  • 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Central Trust Company's 13F filing for Q2 2026, filed 31 Jul 2026.